Trials / Completed
CompletedNCT02492958
SA4Ag Safety, Tolerability, and Immunogenicity Study in Japanese Adults
A Phase 1/2a Placebo-controlled, Randomized, Double-blind, Sponsor-unblinded Trial To Evaluate The Safety, Tolerability, And Immunogenicity Of Staphylococcus Aureus 4-antigen Vaccine (sa4ag) In Japanese Adults
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 136 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 85 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of a single dose of Staphylococcus aureus 4 antigen vaccine in Japanese adults aged 20 to \<86 years.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Staphylococcus aureus 4-antigen vaccine | a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm |
| BIOLOGICAL | Placebo | a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm |
Timeline
- Start date
- 2015-06-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2015-07-09
- Last updated
- 2018-07-30
- Results posted
- 2018-07-30
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02492958. Inclusion in this directory is not an endorsement.